Effects of Nebivolol therapy on hemodynamic parameters and lipid profile compared to other beta blockers in patients with essential hypertension: a systematic review and meta-analysis.

Pub Date : 2024-01-01 DOI:10.22088/cjim.15.1.2
I Made Fermi Wikananda, I Gusti Ngurah Metta Nurcahya, Putu Gede Pradipta Mahardika Wijaya, I Gde Raka Widiana, Dwijo Anargha Sindhughosa
{"title":"Effects of Nebivolol therapy on hemodynamic parameters and lipid profile compared to other beta blockers in patients with essential hypertension: a systematic review and meta-analysis.","authors":"I Made Fermi Wikananda, I Gusti Ngurah Metta Nurcahya, Putu Gede Pradipta Mahardika Wijaya, I Gde Raka Widiana, Dwijo Anargha Sindhughosa","doi":"10.22088/cjim.15.1.2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Besides being commonly used to treat high blood pressure, beta blockers are a family of drugs that are primarily used to regulate irregular cardiac rhythms. Nebivolol is a third generation of beta blockers, which is highly cardioselective, about three times as selective as bisoprolol. In this study, we aimed to evaluate Nebivolol's effectiveness and safety in comparison to other beta blockers.</p><p><strong>Methods: </strong>We searched the online databases PubMed, ScienceDirect, and Cochrane Library for relevant RCTs evaluating Nebivolol's effect on hypertension management. Relative risk (WRR) and weighted mean difference (WMD), with a 95% confidence interval (CI) were utilized to quantify the impact of nebivolol medication in the treatment of hypertension using a random effects model.</p><p><strong>Results: </strong>Twelve RCTs are included in the study, the patient numbers in every attempt ranged from 42-273 and 1456 patients in all were included in this review. Nebivolol does not significantly reduce SBP, DBP and HR compared to other beta blockers (WMD -0.57 mmHg, 95% CI [-1.55; 0.42 mmHg] p=0.12; WMD -0.27 mmHg, 95% CI [-1.36; 0.82 mmHg] p=0.63 ; WMD 0.10 BPM, 95% CI [-4.11;1.31 BPM] p=0.96, respectively). Patients treated with Nebivolol has significantly lower LDL-C (WMD -8.88 mg/dL, 95% CI [-15.28; -2.48 mg/dL] p=0.007) and significantly higher HDL-C (WMD 2.30 mg/dL, 95% CI [0.75; 3.84 mg/dL] p=0.004.</p><p><strong>Conclusions: </strong>According to this study's findings, nebivolol is well tolerated and decreases LDL-C. And higher HDL-C than other beta blocker agents. This review does not recommend nebivolol as first-line treatment in hypertension as Nebivolol does not significantly reduce blood pressure and HR of patients.</p>","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10921108/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22088/cjim.15.1.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Besides being commonly used to treat high blood pressure, beta blockers are a family of drugs that are primarily used to regulate irregular cardiac rhythms. Nebivolol is a third generation of beta blockers, which is highly cardioselective, about three times as selective as bisoprolol. In this study, we aimed to evaluate Nebivolol's effectiveness and safety in comparison to other beta blockers.

Methods: We searched the online databases PubMed, ScienceDirect, and Cochrane Library for relevant RCTs evaluating Nebivolol's effect on hypertension management. Relative risk (WRR) and weighted mean difference (WMD), with a 95% confidence interval (CI) were utilized to quantify the impact of nebivolol medication in the treatment of hypertension using a random effects model.

Results: Twelve RCTs are included in the study, the patient numbers in every attempt ranged from 42-273 and 1456 patients in all were included in this review. Nebivolol does not significantly reduce SBP, DBP and HR compared to other beta blockers (WMD -0.57 mmHg, 95% CI [-1.55; 0.42 mmHg] p=0.12; WMD -0.27 mmHg, 95% CI [-1.36; 0.82 mmHg] p=0.63 ; WMD 0.10 BPM, 95% CI [-4.11;1.31 BPM] p=0.96, respectively). Patients treated with Nebivolol has significantly lower LDL-C (WMD -8.88 mg/dL, 95% CI [-15.28; -2.48 mg/dL] p=0.007) and significantly higher HDL-C (WMD 2.30 mg/dL, 95% CI [0.75; 3.84 mg/dL] p=0.004.

Conclusions: According to this study's findings, nebivolol is well tolerated and decreases LDL-C. And higher HDL-C than other beta blocker agents. This review does not recommend nebivolol as first-line treatment in hypertension as Nebivolol does not significantly reduce blood pressure and HR of patients.

分享
查看原文
与其他β受体阻滞剂相比,奈必洛尔疗法对本质性高血压患者血液动力学参数和血脂状况的影响:系统综述和荟萃分析。
背景:除了常用于治疗高血压外,β受体阻滞剂还是一个主要用于调节不规则心律的药物家族。奈必洛尔是第三代β受体阻滞剂,具有高度心脏选择性,其选择性约为比索洛尔的三倍。本研究旨在评估奈必洛尔与其他β受体阻滞剂相比的有效性和安全性:我们在 PubMed、ScienceDirect 和 Cochrane Library 等在线数据库中搜索了评估奈必洛尔对高血压治疗效果的相关 RCT。采用随机效应模型,利用相对风险(WRR)和加权平均差(WMD)以及95%置信区间(CI)来量化奈必洛尔药物对高血压治疗的影响:本研究共纳入了 12 项临床试验,每次试验的患者人数在 42-273 人之间,共纳入了 1456 名患者。与其他β受体阻滞剂相比,奈必洛尔不能显著降低SBP、DBP和HR(WMD -0.57 mmHg,95% CI [-1.55; 0.42 mmHg] p=0.12;WMD -0.27 mmHg,95% CI [-1.36; 0.82 mmHg] p=0.63;WMD 0.10 BPM,95% CI [-4.11;1.31 BPM] p=0.96)。使用奈必洛尔治疗的患者低密度脂蛋白胆固醇(WMD -8.88 mg/dL,95% CI [-15.28; -2.48 mg/dL] p=0.007)显著降低,高密度脂蛋白胆固醇(WMD 2.30 mg/dL,95% CI [0.75; 3.84 mg/dL] p=0.004)显著升高:本研究结果表明,奈必洛尔具有良好的耐受性,并能降低低密度脂蛋白胆固醇(LDL-C)。与其他β受体阻滞剂相比,奈必洛尔能降低低密度脂蛋白胆固醇,提高高密度脂蛋白胆固醇。本综述不推荐将奈必洛尔作为高血压的一线治疗药物,因为奈必洛尔不能显著降低患者的血压和心率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信